This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech Stock Mailbag: Exelixis, Protalix, Arena

Top-line data from both studies is expected in late 2013 or first half 2014, says Exelixis.

Here are the bullet points summarizing the Exelixis bear thesis of Bio-investor X:

  • Exelixis will miss trial enrollment timelines, especially since on top of Zytiga, Amgen's (AMGN) Xgeva and Dendreon's (DNDN) Provenge (all approved and competing for prostate cancer patients), Algeta's Alpharadin and MDV3100 will be approved soon and also have compassionate-use programs in place.
  • The trials are mis-modeled; the assumptions for survival in the control arm of study 307 are too low. This will make timing of events (deaths) slower and hamper cabo's ability to beat the control arm (survival benefit) by 30%.
  • Study 307 is being conducted at an unproven lower dose of cabo than previously tested, which is likely to reduce the drug's efficacy and make it difficult to win on survival benefit (especially if the control-arm patients live longer than expected.)
  • The pain trial, study 306, is of no value on its own for a cancer drug. FDA recognizes three endpoints for prostate cancer drugs -- survival, quality of life and pain reduction -- but if you don't get a survival claim, forget about premium pricing.

Bio-investor's main beef with Exelixis is Study 307, which he predicts is more likely to fail to demonstrate a survival benefit favoring cabo. Without a survival benefit, FDA will not approve cabo, he says.

I turn the Mailbag over to Bio-Investor X:

"Exelixis and the analysts supporting the company say study 307 will take a year to enroll, with top-line data ready about a year after full enrollment. This timeline is unrealistic.

"Algeta's phase III study of Alpharadin [another prostate cancer therapy] took 36 months from the start of enrollment to the reporting of interim data. The study enrolled 900 patients, with median survival of Alpharadin reaching 14 months compared to 11.2 months for the control arm.

"Johnson & Johnson's Zytiga study took one year to enroll 1,150 patients (with no competition) and 22 months from the start of the trial until interim results. Survival in the Zytiga arm was 14.8 months versus 11.9 months in the control arm.

"Medivation's MDV3100 trial took 26 months to enroll 1,165 patients and reach the interim look. Survival in the '3100 arm was 18.4 months compared to 13.6 months in the control arm.

"With the timelines of these three prostate cancer trials in mind, it seems aggressive to expect Exelixis' study 307 to enroll 960 patients and gather enough events for a top-line data analysis in two years, especially since the competitive environment will be tougher for them. Of course, Exelixis will try to speed up enrollment by seeking patients outside the U.S., but it will still be difficult to find patients that meet the study's enrollment criteria (more so than the three trials mentioned above) and who aren't too sick to tolerate a toxic drug with a narrow therapeutic window like cabo. Who would enroll in this trial ahead of taking Alpharadin or MDV3100, both of which have survival, pain palliation and quality-of-life data?

"Let's turn to an explanation of how Study 307 is mis-modeled. Exelixis designed the study with the assumption that the control arm (patients treated with prednisone) will live an average of 7 months. But look at the post-progression survival for MDV3100 (10.1 months) and for Zytiga (9.2 months). Is it realistic to expect dosing beyond progression? I say no, it isn't. A blend of 10.1 months and 9.2 months is unlikely to give you 7 months survival. The patients in the control arm of Study 307 will live longer than Exelixis modeled.

Stock quotes in this article: EXEL, PLX, ALXA, ARNA, VVUS, MDVN, BMRN, ALXN, GEVA 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs